Isatuximab

Red

Brand Name(s):Sarclisa

Indication:Treatment of relapsed and refractory multiple myeloma in Adults

Rationale:1,2,3

Considered:Sep-20

Review Date:Jan-26

Comments:
Isatuximab, in combination with pomalidomide and dexamethasone is recommended within the cancer drugs fund for relapsed/refractory multiple myeloma in adults, only if they have had 3 previous lines of treatment including lenalidomide & a proteasome inhibitor. NICE TA658 November 2020

Isatuximab, in combination with pomalidomide and dexamethasone, is licensed for treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.